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Severe sepsis remains a clinical challenge today, even in
developed countries, because of the increased age of the
patients and the high burden of antibiotic resistance [1]. In
addition, in recent years, we have become increasingly
aware that, even in the early stages of sepsis, a high pro-
portion of patients experience a severe dysfunction of
native and adaptive immunity, which is closely related to
patients’ outcome [2]. In this context, understanding the
functionality of receptors able to modulate the immune
response, and in particular to downregulate inflammation,
has great importance for designing new therapeutic strat-
egies. Among these molecules, a main role is occupied by
the TAM family of receptor tyrosine kinases, which is
formed by three members, i.e., Tyro3, AxI, and Mer, that
have two vitamin K-dependent ligands, i.e., the growth
arrest-specific protein (Gas)6 and Protein S [3]. In the
September 2013 issue of Intensive Care Medicine, Gui-
gnant et al. [4] explored by an elegant experimental study
the expression of TAM receptors in circulating immune
cells in patients with septic shock and after trauma, and in
healthy volunteers. A significant early alteration of MerTK
expression on monocytes and neutrophils was observed in
patients with septic shock, and a persistent MerTK over-
expression after septic shock was associated with adverse
outcome. The ex vivo analysis showed also a different
MerTK surface expression of healthy monocytes after
48 h incubation with plasma from septic or trauma
patients, supporting the difference in TAM expression
between infection-induced inflammation and sterile
inflammation (i.e., trauma). The study provides new
important data on the mechanisms of immune response in
sepsis, but the true reasons for the observed alterations in
MerKT expression and their role in the complex patho-
physiological context of sepsis remain to be clarified.
TAM receptors are under the control of Toll-like
receptors (TLR), and are widely expressed by cells of the
innate immune system [5]. Activation of TAM receptors by
their ligands triggers a cascade of intracellular events that
culminate in the inhibition of nuclear factor-kappaB (NF-
jB), a crucial proinflammatory molecule, and results in
downregulation of inflammation [6]. When expressed by
monocytes and granulocytes, these receptors (and in par-
ticular MerTK) can also mediate the phagocytosis of
apoptotic cells [7], which is fundamental in order to remove
dead cells without triggering inflammation. Several data
now exist that underline the importance of MerTK activa-
tion in the elimination of potential autoantigens derived by
apoptotic cells, in the inhibition of the production of pro-
inflammatory cytokines, and in the prevention of the
expansion of autoreactive lymphocytes [8–10]. The func-
tional impairment of MerTK promotes not only
autoimmunity but also atherosclerosis, while its overex-
pression is linked to poor prognosis in cancer [11].
The strong relationships existing between TAM
receptors and a proinflammatory molecule such as tumor
necrosis factor-alpha (TNF-a) are reinforced by the
observation that they can interact with a common protein,
the matrix metalloproteinase TNF-a converting enzyme,
also known as ‘‘a disintegrin and a metalloproteinase 17’’
(ADAM17). In order to provide the mature, soluble,
secretable form of TNF-a, ADAM17 cleaves the mem-
brane form of this important proinflammatory cytokine
[12]. Interestingly, ADAM17 is also able to cleave the
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membrane forms of AxI and Mer [13]. Such cleavage
results not only in the internalization of the receptors and
in the transport off the membrane for recycling, but also
in the release of the shortened soluble forms of AxI and
Mer that can act as decoy receptor and bind Gas6 and
Protein S. In turn, the capture of these ligands decreases
the amount of molecules that should bind the membrane
forms of TAM receptors, a crucial event to downregulate
inflammation. Indeed, in chronic active lesions from
patients with multiple sclerosis, it has been shown that the
increase in the soluble forms of these receptors due to
augmented ADAM17 activity is associated with a
sequestration of Gas6 and subsequent increased inflam-
mation [14]. In a mouse model of inflammation, exposure
of lungs to lipopolysaccharide (LPS) enhanced the pro-
duction of soluble Mer [15], whereas the upregulation of
membrane Mer was able to prevent the inflammatory
cascade during lung injury [16].
Considering the aforementioned observations and the
anti-inflammatory role of TAM receptors, the persistent
presence of high amounts of membrane Mer in monocytes
and granulocytes from septic shock patients with adverse
outcome could seem a paradox. However, this phenome-
non could be explained by taking into account the possible
activity of ADAM17, and its capacity to produce soluble
forms of TAM receptors (Fig. 1). Indeed, considering that
ADAM17 is activated by LPS [17], it might be that the ratio
between soluble and membrane forms of TAM receptors
(or even the absolute amount of soluble receptor) becomes
crucial for regulating the antiinflammatory action of Gas6
and Protein S. In this perspective, the increase in the
membrane form of Mer described by Guignant et al. could
be considered a compensatory, antiinflammatory mecha-
nism triggered by innate cells to reduce damage. However,
prolonged ADAM17 activity could cause the accumulation
of the soluble form of Mer, which captures the aforemen-
tioned antiinflammatory molecules and inhibits their
action. Thus, one can hypothesize that those patients who
have high basal ADAM17 activity are at high risk for a
negative outcome. Further studies, including the quantifi-
cation of soluble MerTK, are urgently required to verify
whether this hypothesis is correct, to confirm the impor-
tance of persistent MerTK expression as a novel
biomarker, and, eventually, to explore new therapeutic
strategies for septic shock based upon ADAM17 inhibition.
In fact, several inhibitors of metalloprotease have
already been synthesized and tested in different
pathological settings. Unfortunately, the first generation
and second generations of inhibitors (such as batimastat,
ilomastat, marimastat, and prinomastat) showed problems
related to their bioavailability, pharmacokinetics, and low
selectivity, and were stopped in phase I or II for toxicity
problems [18]. However, due to the large theoretical
therapeutic potential, it is likely that a new generation of
compounds will prove their efficacy very soon and, thus,
may become a new useful therapeutic option in patients
with severe sepsis and specific alterations in TAM or
metalloprotease expression.
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Fig. 1 Possible mechanism linking the persistent increase of
MerTK to the poor outcome of septic shock. Sepsis, through the
induction of a potent inflammatory response (mediated by LPS/
Toll-like receptors, cytokine, and unspecific, massive T cell
activation), causes an increased activity of the matrix metallopro-
teinase TNF-a converting enzyme, known as ADAM17. This
enzyme not only cleaves the membrane form of TNF-a, but also
cleaves the membrane form of the TAM receptor Mer. Soluble Mer
can act as a decoy receptor and capture the growth arrest-specific
protein (Gas)6, whose binding to the membrane form of Mer would
trigger an antiinflammatory response. The increased amount of
membrane Mer on innate immune cells usually favors the
recognition and clearance of apoptotic cells and the inhibition of
NF-jB (thus exerting an antiinflammatory effect). However, such
increase could provide more substrates for the action of ADAM17,
which, in a non-mutually exclusive manner, could result in an
increase of soluble Mer. Thus, it can be hypothesized that the
relative balance between the two forms of Mer, as well as the
amount of soluble Mer, could influence the outcome of septic shock
4. Guignant C, Venet F, Planel S, Demaret
J, Gouel-Che´ron A, Nougier C, Friggeri
A, Allaouchiche B, Lepape A,
Monneret G (2013) Increased MerTK
expression in circulating innate immune
cells of patients with septic shock.
Intensive Care Med 39:1556–1564.
doi:10.1007/s00134-013-3006-9
5. Rothlin CV, Ghosh S, Zuniga EI,
Oldstone MB, Lemke G (2007) TAM
receptors are pleiotropic inhibitors of
the innate immune response. Cell
131:1124–1136
6. Alciato F, Sainaghi PP, Sola D, Castello
L, Avanzi GC (2010) TNF-alpha, IL-6,
and IL-1 expression is inhibited by
GAS6 in monocytes/macrophages.
J Leukoc Biol 87:869–875
7. Lemke G, Rothlin CV (2008)
Immunobiology of the TAM receptors.
Nat Rev Immunol 8:327–336
8. Shao WH, Zhen Y, Eisenberg RA,
Cohen PL (2009) The Mer receptor
tyrosine kinase is expressed on discrete
macrophage subpopulations and mainly
uses Gas6 as its ligand for uptake of
apoptotic cells. Clin Immunol
133:138–144
9. Zizzo G, Hilliard BA, Monestier M,
Cohen PL (2012) Efficient clearance of
early apoptotic cells by human
macrophages requires M2c polarization
and MerTK induction. J Immunol
189:3508–3520
10. Khan TN, Wong EB, Soni C, Rahman
ZS (2013) Prolonged apoptotic cell
accumulation in germinal centers of
Mer-deficient mice causes elevated B
cell and CD4? Th cell responses
leading to autoantibody production.
J Immunol 190:1433–1446
11. Verma A, Warner SL, Vankayalapati H,
Bearss DJ, Sharma S (2011) Targeting
Axl and Mer kinases in cancer. Mol
Cancer Ther 10:1763–1773
12. Moss ML, Jin SL, Becherer JD, Bickett
DM, Burkhart W, Chen WJ, Hassler D,
Leesnitzer MT, McGeehan G, Milla M,
Moyer M, Rocque W, Seaton T,
Schoenen F, Warner J, Willard D
(1997) Structural features and
biochemical properties of TNF-alpha
converting enzyme (TACE).
J Neuroimmunol 72:127–129
13. Thorp E, Vaisar T, Subramanian M,
Mautner L, Blobel C, Tabas I (2011)
Shedding of the Mer tyrosine kinase
receptor is mediated by ADAM17
protein through a pathway involving
reactive oxygen species, protein kinase
Cd, and p38 mitogen-activated protein
kinase (MAPK). J Biol Chem
286:33335–33344
14. Weinger JG, Omari KM, Marsden K,
Raine CS, Shafit-Zagardo B (2009) Up-
regulation of soluble Axl and Mer
receptor tyrosine kinases negatively
correlates with Gas6 in established
multiple sclerosis lesions. Am J Pathol
175:283–293
15. Lee YJ, Han JY, Byun J, Park HJ, Park
EM, Chong YH, Cho MS, Kang JL
(2012) Inhibiting Mer receptor tyrosine
kinase suppresses STAT1, SOCS1/3,
and NF-jB activation and enhances
inflammatory responses in
lipopolysaccharide-induced acute lung
injury. J Leukoc Biol 91:921–932
16. Choi JY, Park HJ, Lee YJ, Byun J,
Youn YS, Choi JH, Woo SY, Kang JL
(2013) Upregulation of Mer receptor
tyrosine kinase signaling attenuated
lipopolysaccharide-induced lung
inflammation. J Pharmacol Exp Ther
344:447–458
17. Arndt PG, Strahan B, Wang Y, Long C,
Horiuchi K, Walcheck B (2011)
Leukocyte ADAM17 regulates acute
pulmonary inflammation. PLoS ONE
6:e19938
18. Murumkar PR, DasGupta S, Chandani
SR, Giridhar R, Yadav MR (2010)
Novel TACE inhibitors in drug
discovery: a review of patented
compounds. Expert Opin Ther Pat
20:31–57
